Efficacy and Safety Evaluation of Levetiracetam + Oxcarbazepine in the Treatment of Patients with Epilepsy Secondary to Stroke

Objective: To evaluate the therapeutic efficacy of levetiracetam (LEV) + oxcarbazepine (OXC) for post-stroke secondary epilepsy (PSE) in the elderly. Methods: 92 patients with PSE admitted to the hospital between July 2021 and July 2023 were selected. Random number table grouping was used, with 46 cases in the combination group, selecting LEV + OXC treatment; and 46 cases in the conventional group, selecting OXC treatment, comparing the treatment effect of the two groups. Results: The total effective rate of the combination group was higher than that of the conventional group, and the difference was statistically significant (P < 0.05). Before treatment, in the comparison of the epilepsy-related indexes and blood indexes between the groups, the difference was not statistically significant (P > 0.05). After treatment, the epilepsy-related indicators as well as blood indicators of the combination group were better than those of the conventional group, and the difference was statistically significant (P < 0.05). The adverse reaction rate of the combination group was lower than that of the conventional group, and the difference was statistically significant (P < 0.05). Conclusion: Implementing LEV + OXC therapy for PSE patients can enhance the effectiveness, improve the degree of epilepsy, regulate the blood indexes, and have high therapeutic safety.